Yongfeng Xu

Chengdu, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.

Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.

Journal: PeerJ
Published: May 02, 2024

tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription.

tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription.

Journal: Oncogene
Published: October 12, 2023

PITX1 plays essential functions in cancer.

PITX1 plays essential functions in cancer.

Journal: Frontiers in oncology
Published: July 05, 2023

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.

Journal: Journal of clinical medicine
Published: December 28, 2022

The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.

The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.

Journal: The Journal of biological chemistry
Published: December 27, 2022

The dual role of p63 in cancer.

The dual role of p63 in cancer.

Journal: Frontiers in oncology
Published: December 05, 2022

Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3.

Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3.

Journal: Journal of clinical medicine
Published: November 12, 2022

Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer.

Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer.

Journal: Journal of clinical medicine
Published: November 06, 2022

Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy.

Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy.

Journal: Signal transduction and targeted therapy
Published: June 07, 2022

NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.

NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.

Journal: Cancer medicine
Published: June 06, 2022

Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

Journal: Journal of clinical medicine
Published: April 18, 2022

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors.

Journal: Genes
Published: April 06, 2022
Showing 1-12 of 15

Last Updated: 09/26/2026